Hemab Therapeutics IPO Priced at $18 Per Share

Key IPO Announcement

Hemab Therapeutics Holdings, Inc. has priced its initial public offering at $18.00 per share. The clinical-stage biotechnology company will offer 16,750,000 shares of common stock, aiming to raise approximately $301.5 million in gross proceeds before underwriting discounts and commissions.

Market Debut and Company Profile

Trading is set to commence on the Nasdaq Global Select Market under the ticker symbol COAG on May 1, 2026. Hemab focuses on developing novel treatments for serious blood coagulation disorders. The company's pipeline includes candidates for conditions like Glanzmann thrombasthenia and Von Willebrand Disease. This IPO is managed by prominent financial institutions including Goldman Sachs, Jefferies, and Evercore ISI.

Impact on the Biotechnology Sector

The successful pricing of the COAG IPO reflects investor interest in the clinical-stage biotechnology space. The capital raised is expected to fund further research and development of Hemab's therapeutic pipeline. Market participants will monitor the stock's performance post-debut as an indicator of sentiment toward biotech ventures focused on rare diseases.

Summary and Outlook

This public offering provides Hemab Therapeutics with significant capital to advance its clinical trials. The market debut on Nasdaq will be a key milestone, with future valuation likely tied to the progress of its lead drug candidates.

FAQ

Q: What is the IPO price for Hemab Therapeutics?
A: The IPO is priced at $18.00 per share.

Q: What is the ticker symbol for Hemab Therapeutics?
A: The company will trade under the ticker symbol COAG on Nasdaq.

Q: How much capital is Hemab Therapeutics expected to raise?
A: The offering is expected to generate gross proceeds of approximately $301.5 million.

Source: Investing.com